Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals

Rhea-AI Filing Summary

Invesco Ltd. reports a significant ownership stake in Ligand Pharmaceuticals Inc. common stock. Invesco, as a parent holding company to its investment advisers, may be deemed to beneficially own 1,218,846 shares of Ligand, representing 6.1% of the outstanding common stock as of June 30, 2026.

Invesco has sole voting power over 1,199,033 shares and sole dispositive power over 1,218,846 shares, with no shared voting or dispositive power. The shares are held of record by Invesco’s advisory clients, who have the right to receive dividends and sale proceeds, and no single client has more than 5% economic ownership of the class.

Key Figures

Beneficially owned shares: 1,218,846 shares Percent of class: 6.1% Sole voting power: 1,199,033 shares +3 more

6 metrics

Beneficially owned shares 1,218,846 shares Shares of Ligand Pharmaceuticals common stock beneficially owned by Invesco Ltd.

Percent of class 6.1% Portion of Ligand Pharmaceuticals common stock class beneficially owned

Sole voting power 1,199,033 shares Shares for which Invesco Ltd. has sole power to vote or direct the vote

Sole dispositive power 1,218,846 shares Shares for which Invesco Ltd. has sole power to dispose or direct disposition

Shared voting power 0 shares Shares with shared power to vote or direct the vote

Shared dispositive power 0 shares Shares with shared power to dispose or direct disposition

Key Terms

beneficially own, sole voting power, sole dispositive power, parent holding company, +1 more

5 terms

beneficially own financial

"may be deemed to beneficially own 1,218,846 shares of the Issuer"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole voting power financial

"Sole power to vote or to direct the vote: 1,199,033"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 1,218,846"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

parent holding company financial

"Invesco Ltd., in its capacity as a parent holding company"

economic ownership financial

"No one person has greater than 5% economic ownership in the securities"

FAQ

What percentage of Ligand Pharmaceuticals (LGND) does Invesco Ltd. own?

Invesco Ltd. may be deemed to beneficially own 6.1% of Ligand Pharmaceuticals’ common stock, corresponding to 1,218,846 shares held of record by its investment advisory clients.

How many Ligand Pharmaceuticals (LGND) shares does Invesco Ltd. control for voting?

Invesco Ltd. reports sole voting power over 1,199,033 shares of Ligand Pharmaceuticals common stock and no shared voting power over any shares.

What is Invesco Ltd.’s dispositive power over Ligand (LGND) shares?

Invesco Ltd. has sole dispositive power over 1,218,846 shares of Ligand Pharmaceuticals common stock and no shared dispositive power, meaning its advisers can direct how these shares are disposed of.

Do any Invesco clients own more than 5% of Ligand (LGND)?

No. The filing states that no one person has greater than 5% economic ownership of Ligand Pharmaceuticals’ common stock among the securities managed by Invesco.

Which Invesco subsidiaries are involved in managing Ligand (LGND) shares?

The filing identifies Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC as subsidiaries connected with the Ligand Pharmaceuticals share holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 02:59 PM Accepted by SEC EDGAR 08/13/2026 - 02:59 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ligand Pharmaceuticals Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

53220K504

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 53220K504

1

Names of Reporting Persons

Invesco Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,199,033.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,218,846.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,218,846.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

HC, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ligand Pharmaceuticals Inc
(b)	Address of issuer's principal executive offices: 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA 92121
Item 2.
(a)	Name of person filing: Invesco Ltd. ("Invesco Ltd.")
(b)	Address or principal business office or, if none, residence: 1331 Spring Street NW, Suite 2500, Atlanta, GA 30309
(c)	Citizenship: Bermuda
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 53220K504
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 1,218,846 shares of the Issuer which are held of record by clients of Invesco Ltd.
(b)	Percent of class: 6.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,199,033
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,218,846
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. No one person has greater than 5% economic ownership in the securities listed above. As holders of record, the relevant clients of Invesco Ltd. have the right to receive or the power to direct the receipt of dividends from, and proceeds from the sale of, the securities listed above.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Invesco Advisers, Inc. Invesco Asset Management Limited Invesco Capital Management LLC
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Invesco Ltd.

Signature:	Robert R. Leveille
Name/Title:	Global Head of Compliance
Date:	08/12/2026